id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-2336-0001,FDA,FDA-2022-D-2336,"Assessing User Fees Under the Overthe-Counter Monograph Drug User Fee Program; Draft Guidance for Industry;
Availability",Notice,Notice of Availability,2022-11-02T04:00:00Z,2022,11,,,2022-11-02T12:14:05Z,2022-23791,0,0,090000648547b381
FDA-2022-D-2336-0002,FDA,FDA-2022-D-2336,Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program; Guidance for Industry; Draft Guidance,Other,Guidance,2022-11-02T04:00:00Z,2022,11,2022-11-02T04:00:00Z,2023-01-04T04:59:59Z,2024-11-07T00:43:58Z,,1,0,090000648546c183